I found this comment from Mark Reddish, former member of board of director and scientific board of Tapimmune, pretty insightful (he's on the yahoo boards):
"...the population of pancreatic pts allows exploration of the technology/antigens etc in solid tumors ‘quickly’. It gets pts enrolled fast."
So perhaps one reason for the trial being put together as it was (non optimized and whatever else) was just to quickly guage if MultiTAA would work for solid tumors.
From where I'm sitting, looks like they got their answer, but to be really technical, it does need a bit more time and development to solidify.
I'm learning that wall street and science / medical community react to very different things. So, to make sense of the perceived value discrepancy, for me, it looks like the results are very encouraging and exciting for science / medical, but a bit hard to parse or even a bit intangible for a re-valuation to happen on wall street. As a result, standard biotech catalyst run up play; unfortunately, shorts take it... for now.
News 
Market Data 
Discover 
